Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Phase 2 Study in Moderate-to-Severe Atopic Dermatitis
NCT01548404Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2012
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Started Apr 2012; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT01548404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01548404.